Long-term Outcome After Admission for Acute Severe Ulcerative Colitis in Oxford: The 1992-1993 Cohort

被引:61
作者
Bojic, D. [1 ,2 ]
Radojicic, Z. [3 ]
Nedeljkovic-Protic, M. [2 ]
Al-Ali, M. [1 ]
Jewell, D. P. [1 ]
Travis, S. P. L. [1 ]
机构
[1] John Radcliffe Hosp, Gastroenterol Unit, Oxford OX3 9DU, England
[2] Univ Clin Ctr Zvezdara, Dept Gastroenterol, Belgrade, Serbia
[3] Univ Belgrade, Inst Stat, Belgrade, Serbia
关键词
severe ulcerative colitis; colectomy; cyclosporin; steroids; FOLLOW-UP; CYCLOSPORINE; INFLIXIMAB; COLECTOMY; DISEASE; COUNTY;
D O I
10.1002/ibd.20843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: To determine the long-term Outcome of patients admitted with acute Severe colitis (ASC) who avoided colectomy on the index admission, a retrospective cohort study was performed. Methods: Patients admitted for intensive treatment of ASC in 1992-1993 previously described for a predictive index of short-term Outcome in severe ulcerative colitis (UC) were followed for a median 122 months (range 3-144). Complete responders (CR) to intensive therapy had <3 nonbloody stools/day on day 7 of the index admission; incomplete responders (IR) were all others who avoided colectomy oil that admission, Main outcome measures were colectomy-free survival, time to colectomy, and duration of steroid-free remission. Results: In all, 6/19 CR (32%) came to colectomy compared to 10/13 IR (P = 0.016; relative risk 3.33, 95% confidence interval [CI] 1.12-9.9). The median +/- interquartile range time to cotectomy was 28 +/- 47 months (range 6-99) for CR who came to colectomy versus 7.5 +/- 32 (3-72) months for IR (P = 0.118). Among the IR, 7/13 came to colectomy within 12 months, and all within 6 years From the index admission. The longest period of steroid-free remission was 42 +/- 48 (0-120) months for CR, but 9 +/- 20 (1-35) months for IR (P = 0.011). Conclusions: One week after admission with ASC in the prebiologic era. IRs had a 50% chance of colectomy within a year and 70% within 5 years, despite cyclosporin and azathioprine where appropriate. The maximum duration of remission in CRs was almost 5 times longer than IRs. It is unknown whether biologics change the long-term Outcome.
引用
收藏
页码:823 / 828
页数:6
相关论文
共 18 条
[1]   Ciclosporin use in acute ulcerative colitis: a long-term experience [J].
Campbell, S ;
Travis, S ;
Jewell, D .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (01) :79-84
[2]   COURSE AND PROGNOSIS OF ULCERATIVE COLITIS [J].
EDWARDS, FC ;
TRUELOVE, SC .
GUT, 1963, 4 (04) :299-+
[3]   CLINICAL-PATTERNS, NATURAL-HISTORY, AND PROGRESSION OF ULCERATIVE-COLITIS - A LONG-TERM FOLLOW-UP OF 1116 PATIENTS [J].
FARMER, RG ;
EASLEY, KA ;
RANKIN, GB .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (06) :1137-1146
[4]   Response of refractory colitis to intravenous or oral tacrolimus (FK506) [J].
Fellermann, K ;
Tanko, T ;
Herrlinger, KR ;
Witthoeft, T ;
Homann, N ;
Bruening, A ;
Ludwig, D ;
Stange, EF .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (05) :317-324
[5]   CYCLOSPORIN IN ULCERATIVE-COLITIS [J].
GUPTA, S ;
KESHAVARZIAN, A ;
HODGSON, HJF .
LANCET, 1984, 2 (8414) :1277-1278
[6]   LONG-TERM PROGNOSIS IN ULCERATIVE-COLITIS - BASED ON RESULTS FROM A REGIONAL PATIENT GROUP FROM THE COUNTY OF COPENHAGEN [J].
HENDRIKSEN, C ;
KREINER, S ;
BINDER, V .
GUT, 1985, 26 (02) :158-163
[7]   Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006 [J].
Jakobovits, S. L. ;
Jewell, D. P. ;
Travis, S. P. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) :1055-1060
[8]  
Jakobovits SL, 2006, BR MED B, V75-76, P131, DOI DOI 10.1093/BMB/LDL001]
[9]   Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study [J].
Järnerot, G ;
Hertervig, E ;
Friis-Liby, I ;
Blomquist, L ;
Karlé, P ;
Grännö, C ;
Vilien, M ;
Ström, M ;
Danielsson, Å ;
Verbaan, H ;
Hellström, PM ;
Magnuson, A ;
Curman, B .
GASTROENTEROLOGY, 2005, 128 (07) :1805-1811
[10]   Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up [J].
Kohn, A. ;
Daperno, M. ;
Armuzzi, A. ;
Cappello, M. ;
Biancone, L. ;
Orlando, A. ;
Viscido, A. ;
Annese, V. ;
Riegler, G. ;
Meucci, G. ;
Marrollo, M. ;
Sostegni, R. ;
Gasbarrini, A. ;
Peralta, S. ;
Prantera, C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (05) :747-756